245 related articles for article (PubMed ID: 32882760)
1. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
3. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
5. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
7. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
8. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
9. Targeting the
Amaya ML; Pollyea DA
Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
[TBL] [Abstract][Full Text] [Related]
10. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
12. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
[TBL] [Abstract][Full Text] [Related]
13. Enasidenib for the treatment of acute myeloid leukemia.
Dugan J; Pollyea D
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
[TBL] [Abstract][Full Text] [Related]
14. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
[No Abstract] [Full Text] [Related]
15. IDH2 inhibition in AML: Finally progress?
Stein EM
Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
[TBL] [Abstract][Full Text] [Related]
16. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra KC; DiNardo CD
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
[TBL] [Abstract][Full Text] [Related]
17. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
18. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.
Thomas D; Majeti R
Cancer Discov; 2017 May; 7(5):459-461. PubMed ID: 28461409
[TBL] [Abstract][Full Text] [Related]
20. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
